Early-life low-calorie sweetener consumption disrupts glucose regulation, sugar-motivated behavior, and memory

Linda Tsan1,2, Sandrine Chometton2, Anna Mr Hayes2

  • 1Neuroscience Graduate Program and.

JCI Insight
|September 13, 2022
PubMed

Insights

Early consumption of low-calorie sweeteners (LCS) affects memory and glucose regulation in adult rats, even without weight gain. These findings highlight potential long-term impacts of LCS on cognitive and metabolic health.

Area of Science:

  • Neuroscience
  • Metabolic Science
  • Toxicology

Background:

  • Childhood consumption of low-calorie sweeteners (LCS) is rising, driven by obesity concerns and widespread availability.
  • Mechanistic data on the long-term effects of early-life LCS exposure on cognitive and physiological functions remain limited.

Purpose of the Study:

  • To investigate the long-term metabolic, behavioral, gut microbiome, and brain transcriptomic consequences of adolescent LCS consumption in a rodent model.
  • To assess the impact of acesulfame potassium, saccharin, and stevia on adult outcomes following early-life exposure.

Main Methods:

  • Rodents were administered daily LCS (acesulfame potassium, saccharin, or stevia) during adolescence.
  • Adult outcomes assessed included metabolic parameters, behavior, gut microbiome composition, and brain transcriptomics (RNA-Seq) in specific regions.

Main Results:

  • Adolescent LCS consumption impaired hippocampal-dependent memory and altered postoral glucose handling in adulthood, independent of weight changes.
  • Long-term effects included reduced lingual sweet taste receptor expression and modified sugar-motivated behaviors.
  • Brain analyses revealed sex-dependent alterations in collagen and synaptic signaling pathways in the hippocampus and nucleus accumbens.

Conclusions:

  • Habitual early-life LCS consumption has lasting effects on glucoregulation, sugar-seeking behavior, and memory in rats.
  • These impacts may stem from changes in nutrient transporters, sweet taste receptors, and central gene expression pathways.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...